Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 9 Skin Neoplasms 2 Neoplasms 2 Uveal Melanoma 1 Triple Negative Breast Neoplasms 1 The Initial Aim of This Project is to Perform in Vitro Validation of Neoepitope Candidates Selected From Available Mutanome Data 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Healthy Volunteer 1 Healthy Adults 1 Glioblastoma 1 Eye Neoplasms 1 Esophageal Neoplasms 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Carcinoma 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

pembrolizumab 161 Carboplatin 145 Paclitaxel 125 Cyclophosphamide 94 130-nm albumin-bound paclitaxel 66 Capecitabine 64 Gemcitabine 54 Doxorubicin 50 Albumin-Bound Paclitaxel 45 Taxes 42 atezolizumab 41 Cisplatin 38 sacituzumab govitecan 34 Nivolumab 34 olaparib 32 Epirubicin 32 Specimen Handling 28 Docetaxel 28 eribulin 27 Bevacizumab 26 durvalumab 25 Drug Therapy 25 Biopsy 24 camrelizumab 23 Magnetic Resonance Spectroscopy 22 toripalimab 19 Radiotherapy 17 spartalizumab 16 Everolimus 15 veliparib 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Triple Negative Breast Neoplasms × Peptides × Clear all

NCT06195618 2025-06-25

TEBICA003 TNBC

Universidad Nacional de Colombia

Phase 1 Not yet recruiting

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡